Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$5.30 USD
-0.15 (-2.75%)
Updated Apr 25, 2024 11:12 AM ET
5-Strong Sell of 5 5
F Value F Growth A Momentum F VGM
Cash flow Statements
Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -111.40 | -278.48 | -180.09 | -169.43 | -146.43 |
Depreciation/Amortization & Depletion | 32.79 | 34.70 | 39.87 | 35.76 | 55.02 |
Net Change from Assets/Liabilities | -25.48 | 0.90 | 79.98 | -26.04 | 2.68 |
Net Cash from Discontinued Operations | -219.60 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 43.66 | 56.59 | 45.45 | 116.97 | 30.51 |
Net Cash From Operating Activities | -280.02 | -186.29 | -14.79 | -42.74 | -58.21 |
Property & Equipment | -0.67 | -0.19 | -5.10 | -6.77 | -0.20 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -109.37 | -3.40 | -113.47 | 58.52 | 35.43 |
Other Investing Activities | 165.81 | -28.97 | -19.05 | -113.08 | -15.37 |
Net Cash from Investing Activities | 55.78 | -32.55 | -137.62 | -61.33 | 19.86 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 219.07 | 24.13 | 237.78 | 135.42 | 1.62 |
Issuance (Repayment) of Debt | 0.00 | 104.93 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.32 | -11.48 | -6.09 | -7.70 | -3.70 |
Net Cash from Financing Activities | 218.75 | 117.57 | 231.68 | 127.71 | -2.08 |
Effect of Exchange Rate Changes | 1.98 | -2.79 | 1.71 | -1.31 | -0.01 |
Net Change In Cash & Equivalents | -3.51 | -104.07 | 80.98 | 22.34 | -40.44 |
Cash at Beginning of Period | 61.69 | 165.75 | 84.77 | 62.44 | 102.87 |
Cash at End of Period | 58.18 | 61.69 | 165.75 | 84.77 | 62.44 |
Diluted Net EPS | -1.50 | -4.37 | -3.01 | -3.56 | -3.46 |
Fiscal Year End for Travere Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -111.40 | -21.23 | -171.96 | -86.33 |
Depreciation/Amortization & Depletion | NA | 32.79 | 23.86 | 20.12 | 9.55 |
Net Change from Assets/Liabilities | NA | -25.48 | -32.58 | -28.53 | -22.07 |
Net Cash from Discontinued Operations | NA | -219.60 | -215.08 | 0.00 | 0.00 |
Other Operating Activities | NA | 43.66 | 35.47 | 29.96 | 17.74 |
Net Cash From Operating Activities | NA | -280.02 | -209.55 | -150.41 | -81.12 |
Property & Equipment | NA | -0.67 | -0.64 | 0.00 | -0.63 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -109.37 | -96.72 | -28.79 | -9.07 |
Other Investing Activities | NA | 165.81 | 170.09 | -31.80 | -27.34 |
Net Cash from Investing Activities | NA | 55.78 | 72.73 | -60.59 | -37.04 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 219.07 | 219.07 | 218.92 | 218.13 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.32 | -0.44 | 0.35 | -1.13 |
Net Cash from Financing Activities | NA | 218.75 | 218.63 | 219.26 | 217.00 |
Effect of Exchange Rate Changes | NA | 1.98 | 0.75 | 0.93 | 0.85 |
Net Change In Cash & Equivalents | NA | -3.51 | 82.56 | 9.19 | 99.69 |
Cash at Beginning of Period | NA | 61.69 | 61.69 | 61.69 | 61.69 |
Cash at End of Period | NA | 58.18 | 144.24 | 70.87 | 161.38 |
Diluted Net EPS | NA | -1.07 | 1.97 | -1.13 | -1.27 |